Biotransformation of ginsenosides Rb1, Rg3 and Rh2 in rat gastrointestinal tracts
© Qian and Cai; licensee BioMed Central Ltd. 2010
Received: 25 January 2010
Accepted: 26 May 2010
Published: 26 May 2010
Ginsenosides such as Rb1, Rg3 and Rh2 are major bioactive components of Panax ginseng. This in vivo study investigates the metabolic pathways of ginsenosides Rb1, Rg3 and Rh2 orally administered to rats.
High performance liquid chromatography-mass spectrometry (LC-MS) and tandem mass spectrometry (MS-MS) techniques, particularly liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS), were used to identify the metabolites.
Six metabolites of Rb1, six metabolites of Rg3 and three metabolites of Rh2 were detected in the feces samples of the rats. Rh2 was a metabolite of Rb1 and Rg3, whereas Rg3 was a metabolite of Rb1. Some metabolites such as protopanaxadiol and monooxygenated protopanaxadiol are metabolites of all three ginsenosides.
Oxygenation and deglycosylation are two major metabolic pathways of the ginsenosides in rat gastrointestinal tracts.
Panax ginseng (Renshen) is used in Chinese medicines to treat various conditions such as debility, ageing, stress, diabetes, insomnia and sexual inadequacy [1–3]. The major bioactive components of P. ginseng are O-glycosides of the triterpen dammarane saponins known as ginsenosides [4, 5] which exhibit properties such as anti-inflammation and anti-tumor [6–8]. Over 80 ginsenosides have been isolated from P. ginseng . Rb1, Rg3 and Rh2 are three major ginsenosides with various bioactivities.
Rb1, which is the most abundant (0.22-0.62%) among all ginsenosides , protects against free radical damage, maintains normal cholesterol and blood pressure  and inhibits the induction phase of long-term potentiation by high frequency stimulation in the dentate gyrus of the brain . Rb1 also rescues hippocampal neurons from lethal ischemic damage  and delays neuronal death from transient forebrain ischemia in vitro . Rg3 is used as the major active component in an anti-tumor and anti-cancer drug in China . The cytotoxicity of ginsenoside Rg3 against tumor cells increases when Rg3 is metabolized into Rh2 or protopanaxadiol . The metabolic transformation of Rg3 into protopanaxadiol also increases the activity against Helicobacter pylori. Recently, in vitro biotransformation of ginsenosides was reported. The metabolites were identified by high-resolution tandem mass spectrometry. Degradation and bioconversion routes of the different ginsenosides at acidic (gastric) conditions and in the presence of intestinal microbiota were elaborated .
High performance liquid chromatography (HPLC) is a powerful chemical analysis technology that allows complex mixtures to be transformed into separated components. Mass spectrometry (MS) has progressed extremely rapidly during the last decade; especially in production, separation and ejection of ions, data acquisition and data reduction. Compared to other detectors, the advantages of the mass spectrometer are that in many cases it can provide absolute identification, not only structural information from the molecule under investigation but the molecular weight of the analyte.
Due to the specificity and sensitivity of LC-MS, especially in combination with MS-MS, it is powerful in identification of drug metabolites. Common biotransformation, e.g., oxidative reactions (hydroxylation), conjugation reactions to produces sulphates, glucuronides, glutathiones or other conjugates, hydrolysis of esters and amides, and reduction reactions, can be evaluated from just the knowledge of the molecular mass of the metabolites. Combination of the molecular-mass and possible biotransformation products, predicted by computer-aided molecular modeling approaches, enables the confirmation of metabolic pathways. Further confirmation and/or structure elucidation of metabolites is possible using MS-MS methods . The identification of the metabolites of antihistamine compounds is feasible by using thermospray LC-MS and LC-MS-MS [18, 19]. The present study aims to investigate the biotransformation of ginsenosides Rb1, Rg3 and Rh2 orally administered to rats by using LC-MS and MS-MS.
Ginsenosides Rb1, Rg3 and Rh2 (purity >99%) were provided by the Chinese Medicine Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, China. HPLC-grade methanol was purchased from Acros Organics (USA). A Mili-Q Ultra-pure water system (Millipore, USA) was used to provide water for all the experiments. Other chemicals (analytical grade) were purchased from Sigma (USA).
Administration of ginsenosides
Water soluble Rb1, Rg3 and Rh2 were administered to three groups (n = 3 in each group) of male Sprague Dawley rats (body weight 200-220 g; age 6-7 weeks) respectively at a dose of 100 mg/kg body weight with 2 ml dosing solution. The protocols of the animal study were fully complied with the University policy on the care and use of animals and with related codes of practice. The animal experiments were conducted with the licenses granted by Hong Kong Hygiene and Health Department. Rat feces samples were collected at such intervals: 0 to 120 hours for Rb1 (half-life 16.7 hours), 0 to 24 hours for Rg3 (half-life 18.5 minutes) and 0 to 48 hours for Rh2 (half-life 16 minutes)[20–22].
Feces sample preparation
Each feces sample of each rat was suspended in 150 ml of water and then extracted with n-butanol (100 ml × 3). The extract was dried and the residue was dissolved in 1 ml of methanol. After centrifugation at 12000 rpm for 20 minutes (Eppendorf Centrifuge 5415R, Hamburg, Germany), 2 μl of the supernatant was analyzed with LC-Ms and LC-MS-MS for the identification of the ginsenosides and their metabolites. The blank feces (baseline) were collected from the same Sprague Dawley rat prior to the administration of ginsenosides, prepared and analyzed with the same method as the experimental groups.
HPLC separation was performed with a LC system coupled with an auto-sampler and a micro mode pump (HP1100, Agilent Technologies, USA). A reversed-phase column (Waters, Xterra MS-C8, 2.1 × 100 mm, 3.5 μm) was used to separate the ginsenosides and their metabolites. The auto-sampler was set at 10°C. Mobile phase consisted of two eluents: water (A) and methanol (B). Gradient elution was 40% B in 0-4 minutes, 40-90% B in 4-5 minutes, 90% B in 5-35 minutes, 90-40% B in 35-36 minutes and 40% B in 36-42 minutes at a flow rate of 100 μl/min. Effluent from the LC column was diverted to waste for the first 12 minutes following the injection, and then diverted to the MS ion source.
MS experiments were performed on a quadruple-time of flight (Q-TOF) tandem mass spectrometer API Q-STAR Pulsar I (Applied Biosystems, USA). Negative or positive ion mode in electrospray ionization (ESI) was used to analyze ginsenosides and their metabolites in rat feces samples. The following parameters of the turbo-ionspray for positive ion mode were used: ionspray voltage 5500 V, declustering potential 1 (DP1) 90 V, focusing potential (FP) 265 V and declustering potential 2 (DP2) 10 V, collision energy (CE) 55 eV for MS-MS analysis. For negative ion mode, the parameters were: ionspray voltage -4200 V, declustering potential 1 (DP1) -90 V, focusing potential (FP) -265 V and declustering potential 2 (DP2) 10 V, collision energy (CE) -60 eV for MS-MS analysis. For both positive and negative ion mode, the ion source gas 1 (GS1), gas 2 (GS2), curtain gas (CUR) and collision gas (CAD) were 20, 15, 25 and 3, respectively. The temperature of GS2 was set at 400°C.
Results and Discussion
Metabolites of Rb1 in rat feces
The deglycosylated metabolites were also confirmed by the LC-MS analysis of authentic standards of Rd, Rg3, Rh2 and protopanaxadiol. Moreover, the LC-MS-MS analysis indicated that these deglycosylated metabolites were subsequently oxygenated in digestive tracts. Thus, deglycosylation and subsequent oxygenation are the major metabolic pathways of orally administered Rb1 in rats. Figure 1 illustrates the proposed metabolic pathways of Rb1.
Metabolites of Rg3 in rat feces
Metabolites of Rh2 in rat feces
Oxygenation and deglycosylation are two major metabolic pathways of the ginsenosides in rat gastrointestinal tracts. Furthermore, Rh2 is a metabolite of Rb1 and Rg3, whereas Rg3 is a metabolite of Rb1. Some metabolites such as protopanaxadiol and monooxygenated protopanaxadiol are metabolites of all three ginsenosides.
High performance liquid chromatography
High performance liquid chromatography coupled with mass spectrometry
Tandem mass spectrometry
High performance liquid chromatography coupled with tandem mass spectrometry
Quadruple-time of flight
Liquid chromatography electrospray ionization mass spectrometry.
This work was supported by earmarked grants HKBU2154/04 M from the University Grants Committee (RGC) of Hong Kong.
- Crellin JK, Philpott J: A reference guide to medicinal plants: herbal medicine past and present. 1990, Durham: Duke University Press, 2:Google Scholar
- Chang MS, Lee SG, Rho HM: Transcriptional activation of Cu/Zn superoxide dismutase and catalase genes by panaxadiol ginsenosides extracted from Panax ginseng. Phytother Res. 1999, 13: 641-644. 10.1002/(SICI)1099-1573(199912)13:8<641::AID-PTR527>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
- Lewis R, Wake G, Court G, Court JA, Pickering AT, Kim YC, Perry EK: Non-ginsenoside nicotinic activity in ginseng species. Phytother Res. 1999, 13: 59-64. 10.1002/(SICI)1099-1573(199902)13:1<59::AID-PTR423>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Karikura M, Miyase T, Tanizawa H, Taniyama T, Takino Y: Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VII. Comparison of the decomposition modes of ginsenoside-Rb1 and -Rb2 in the digestive tract of rats. Chem Pharm Bull (Tokyo). 1991, 39 (9): 2357-2361.View ArticleGoogle Scholar
- Takino Y: Studies on the pharmacodynamics of ginsenoside-Rg1, -Rb1 and -Rb2 in rats. Yakugaku Zasshi (Japanese). 1994, 114 (8): 550-564.Google Scholar
- Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ: Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol. 1992, 148 (5): 1519-1525.PubMedGoogle Scholar
- Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, Azuma I: Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol Pharm Bull. 1994, 17 (5): 635-639.View ArticlePubMedGoogle Scholar
- Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saiki I, Tono-oka S, Samukawa K, Azuma I: Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bull. 1995, 18 (9): 1197-1202.View ArticlePubMedGoogle Scholar
- Dou D, Chen Y, Ren J: Ocotillone-type ginsenoside from leaves of Panax ginseng. J Chin Pharm Sci. 2002, 11 (4): 119-121.Google Scholar
- Li X, Guo R, Li L: Pharmacological variations of Panax ginseng C.A. Meyer during processing. Zhongguo Zhong Yao Za Zhi. 1991, 16 (1): 62-Google Scholar
- Wang XY, Zhang JT: Effect of ginsenoside Rb1 on long-term potentiation in the dentate gyrus of anaesthetized rats. J Asian Nat Prod Res. 2003, 5 (1): 1-4. 10.1080/10286020290029009.View ArticlePubMedGoogle Scholar
- Lim JH, Wen TC, Matsuda S, Tanaka J, Maeda N, Peng H, Aburaya J, Ishihara K, Sakanaka M: Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci Res. 1997, 28 (3): 191-200. 10.1016/S0168-0102(97)00041-2.View ArticlePubMedGoogle Scholar
- Wen TC, Yoshimura H, Matsuda S, Lim JH, Sakanaka M: Ginseng root prevents learning disability and neuronal loss in gerbils with 5-minute forebrain ischemia. Acta Neuropathol. 1996, 91 (1): 15-22. 10.1007/s004010050387.View ArticlePubMedGoogle Scholar
- Huang JY, Sun Y, Fan QX, Zhang YQ: Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2009, 7 (11): 1047-51. 10.3736/jcim20091105.View ArticlePubMedGoogle Scholar
- Bae EA, Han MJ, Choo MK, Park SY, Kim DH: Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharm Bull. 2002, 25 (1): 58-63. 10.1248/bpb.25.58.View ArticlePubMedGoogle Scholar
- Kong H, Wang M, Venema K, Maathuis A, Heijden van der R, Greef van der J, Xu G, Hankemeier T: Bioconversion of red ginseng saponins in the gastro-intestinal tract in vitro model studied by high-performance liquid hromatography-high resolution Fourier transform ion cyclotron resonance mass spectrometry. J Chromatogr A. 2009, 1216 (11): 2195-2203. 10.1016/j.chroma.2008.11.030.View ArticlePubMedGoogle Scholar
- Yost RA, Perchalski RJ, Brotherton HO, Johnson JV, Budd MB: Pharmaceutical and clinical analysis by tandem mass spectrometry. Talanta. 1984, 31 (10 Pt 2): 929-35. 10.1016/0039-9140(84)80223-4.View ArticlePubMedGoogle Scholar
- Korfmacher WA, Holder CL, Betowski LD, Mitchum RK: Characterization of doxylamine and pyrilamine metabolites via thermospray/mass spectrometry and tandem mass spectrometry. Biomed Environ Mass Spectrom. 1988, 15 (9): 501-8. 10.1002/bms.1200150907.View ArticlePubMedGoogle Scholar
- Lay JO, Getek TA, Kelly DW, Slikker W, Korfmacher WA: Fast-atom bombardment and thermospray mass spectrometry for the characterization of two glucuronide metabolites of methapyrilene. Rapid Commun Mass Spectrom. 1989, 3 (3): 72-5. 10.1002/rcm.1290030306.View ArticlePubMedGoogle Scholar
- Qian T, Cai Z, Wong RNS, Jiang ZH: Liquid chromatography-mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun Mass Spectrom. 2005, 19: 3549-3554. 10.1002/rcm.2232.View ArticlePubMedGoogle Scholar
- Qian T, Cai Z, Wong RNS, Mak NK, Jiang ZH: In vivo metabolic and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B. 2005, 816: 223-232. 10.1016/j.jchromb.2004.11.036.View ArticleGoogle Scholar
- Qian T, Jiang ZH, Cai Z: High performance liquid chromatography coupled with tandem mass spectrometry applied for in vivo metabolic study of ginsenoside Rb1. Anal Biochem. 2006, 352 (1): 87-96. 10.1016/j.ab.2006.02.025.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.